Clinical Trial Update: Tipifarnib in Treating Patients With Metastatic Malignant Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating tipifarnib for patients with metastatic (recurrent or Stage IV) melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Tipifarnib (tipifarnib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Status: COMPLETED